Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

NanoBiCar: A novel immunotherapy for infectious diseases

Project description

Cost-effective immunotherapy platforms target bacterial infectious diseases

Bacterial infections contribute to 20 % of global mortality. Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the leading cause of mortality from a single infectious agent. Multidrug-resistant (MDR) TB poses a significant threat. A fourth of the population is latently infected, many with MDR strains. Current treatments face challenges including lack of specificity, ineffective access to intracellular bacteria and increasing antibiotic resistance. The EIC-funded NanoBiCar project aims to revolutionise bacterial infection treatment through innovative immunotherapy leveraging mRNA-loaded lipid nanoparticles. Targeting Mtb and elimination of intra- and extracellular bacteria as proof of concept, the project will deliver safe, cost-effective solutions suitable for latent, acute and chronic infections suitable for use in high-burden, low-resource settings.

Objective

It is estimated that 20% of global mortality is associated with bacterial infections. The current treatment is based on the use of antibiotics, but nonspecific effects, difficulty in reaching intracellular bacteria, and the generation of antimicrobial resistance limit its effectiveness. Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent: Mycobacterium tuberculosis (Mtb). Multidrug-resistant TB (MDR-TB) is a major threat to global health security. A quarter of the population is latently infected with Mtb, many of them MDR strains, so preventing new cases of this growing reservoir is a priority. Immunotherapy is an alternative option, but its effectiveness is based on the immune response capacity of a compromised host. NanoBiCar's long-term vision is to revolutionize the current treatment of bacterial infections with a groundbreaking and innovative immunotherapeutic approach, overcoming many of the problems associated with treatment, with potential application beyond this field. Using TB as a proof of concept, three immunotherapeutic platforms, using mRNAs encapsulated in lipid nanoparticles, not tested in bacterial diseases will be used to eliminate intra (IC) and extracellular (EC) bacteria. These immunotherapeutic methods are safe, economical, accessible, ready-to-use, and specific, targeting latent/ acute/chronic infections, without generating resistance and suitable for use in high-burden, low-resource settings; effective regardless of the antibiotic resistance of the strain and its niche (IC or EC), the genetic background of the host and the degree of immunocompetence.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2024-PATHFINDEROPEN-01

See all projects funded under this call

Coordinator

UNIVERSITAT POLITECNICA DE VALENCIA
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 614 338,75
Address
CAMINO DE VERA SN EDIFICIO 3A
46022 VALENCIA
Spain

See on map

Region
Este Comunitat Valenciana Valencia/València
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 702 448,75

Participants (10)

My booklet 0 0